Rapport d'analyse du marché des spectromètres de masse en Asie-Pacifique : taille, part de marché et tendances – Aperçu du secteur et prévisions jusqu'en 2033

Taille du marché des appareils de spectrométrie de masse en Asie-Pacifique

• Le marché des spectromètres de masse en Asie-Pacifique était évalué à 1,41 milliard de dollars en 2025  et devrait atteindre  2,27 milliards de dollars d'ici 2033 , soit un TCAC de 6,19 % au cours de la période de prévision.
• La croissance du marché est largement alimentée par l'adoption croissante de technologies analytiques avancées dans les laboratoires pharmaceutiques, biotechnologiques, cliniques et environnementaux, ainsi que par les progrès technologiques constants des spectromètres de masse qui permettent une sensibilité, une précision et un débit accrus.
• De plus, la demande croissante d'analyses moléculaires précises, le développement des applications en protéomique, métabolomique, découverte de médicaments et diagnostic clinique, ainsi que le besoin de solutions analytiques automatisées et à haut débit, font des spectromètres de masse des outils essentiels des flux de travail des laboratoires modernes. Ces facteurs convergents accélèrent l'adoption des solutions de spectrométrie de masse, stimulant ainsi significativement la croissance du secteur.

Analyse du marché des appareils de spectrométrie de masse en Asie-Pacifique

• Les appareils de spectrométrie de masse, notamment les systèmes LC-MS, GC-MS, MALDI-TOF et ICP-MS, sont de plus en plus essentiels dans les laboratoires modernes en raison de leur haute sensibilité, de leur précision et de leur capacité à effectuer des analyses moléculaires, protéomiques, métabolomiques et cliniques complexes dans les domaines pharmaceutique, biotechnologique, environnemental et du diagnostic clinique.
• La demande croissante d'appareils de spectrométrie de masse est principalement alimentée par le développement d'applications dans la découverte de médicaments, le diagnostic clinique, la sécurité alimentaire et la surveillance environnementale, ainsi que par le besoin de solutions analytiques rapides, à haut débit et automatisées dans les laboratoires de recherche et industriels.
• La Chine a dominé le marché des spectromètres de masse en 2025, avec une part de revenus de 38,4 %, grâce à l'expansion rapide des industries pharmaceutiques et biotechnologiques, à l'augmentation des investissements dans les infrastructures de laboratoire et à l'adoption de technologies analytiques avancées dans les laboratoires de recherche et cliniques.
• L'Inde devrait connaître la croissance la plus rapide sur le marché des spectromètres de masse au cours de la période de prévision, avec un taux de croissance annuel composé (TCAC) de 11,2 % entre 2026 et 2033. Cette croissance sera soutenue par l'essor de la recherche et du développement, les initiatives gouvernementales visant à renforcer les capacités analytiques et la demande croissante des laboratoires pharmaceutiques, cliniques et agroalimentaires.
• Le segment de la spectrométrie de masse hybride a dominé le marché en 2025, représentant 44,5 % des revenus, grâce à sa polyvalence permettant de combiner plusieurs analyseurs de masse pour fournir des mesures de masse précises et à haute résolution sur des échantillons complexes.

Portée du rapport et segmentation du marché des appareils de spectrométrie de masse

Tendances du marché des spectromètres de masse en Asie-Pacifique

Précision analytique accrue et capacités de débit élevé

• L'adoption croissante d'instruments à haute résolution et à haut débit dans les laboratoires pharmaceutiques, cliniques et de recherche constitue une tendance majeure et en pleine accélération sur le marché mondial des spectromètres de masse. Ces appareils permettent aux chercheurs d'analyser des échantillons biologiques et chimiques complexes avec une précision exceptionnelle, autorisant ainsi la quantification et l'identification précises de molécules à de très faibles concentrations.
  • Par exemple, en mars 2024, Thermo Fisher Scientific a lancé son spectromètre de masse Orbitrap Exploris 480, offrant une protéomique à ultra-haute résolution et une sensibilité accrue, soutenant la découverte de médicaments, l'analyse des biomarqueurs et les diagnostics cliniques.
• L'intégration croissante de la spectrométrie de masse avec des technologies complémentaires, telles que la chromatographie liquide (LC-MS) et la chromatographie en phase gazeuse (GC-MS), élargit les capacités analytiques et améliore l'efficacité des flux de travail en laboratoire.
• On observe une tendance croissante à la miniaturisation et à la généralisation des systèmes de spectrométrie de masse de paillasse, permettant aux laboratoires disposant d'un espace et d'un budget limités d'adopter des solutions analytiques avancées sans compromettre les performances.
• L'essor de la préparation automatisée des échantillons, des systèmes de manipulation robotisés et des plateformes d'analyse de données basées sur le cloud accélère encore la demande d'instruments de spectrométrie de masse en permettant un débit plus élevé et des délais d'exécution plus courts pour les études à grande échelle.

Dynamique du marché des spectromètres de masse en Asie-Pacifique

Conducteur

Demande croissante en matière de recherche pharmaceutique et clinique

• Le besoin croissant de caractérisation moléculaire précise dans le développement de médicaments, la protéomique, la métabolomique et la découverte de biomarqueurs favorise l'adoption des spectromètres de masse. Les laboratoires investissent dans des instruments de pointe pour améliorer la fiabilité, la rapidité et la reproductibilité des résultats.
  • Par exemple, en juillet 2023, Bruker Corporation a lancé le système timsTOF Pro 2 pour la recherche en protéomique, permettant un profilage protéique plus rapide avec une sensibilité élevée, qui a été largement adopté dans la R&D pharmaceutique et les laboratoires cliniques du monde entier.
• L'augmentation des investissements dans les infrastructures de santé et des dépenses de R&D, tant dans les marchés développés que dans les marchés émergents, favorise le déploiement de plateformes de spectrométrie de masse avancées dans les hôpitaux, les établissements universitaires et les centres de recherche.
• La prévalence croissante des maladies chroniques et complexes, notamment le cancer, les troubles cardiovasculaires et les maladies métaboliques, accroît la demande de solutions diagnostiques et thérapeutiques basées sur la spectrométrie de masse.
• L'expansion des cadres réglementaires et des exigences de contrôle de la qualité dans la fabrication pharmaceutique encourage les laboratoires à mettre en œuvre des spectromètres de masse de haute précision afin de garantir le respect des normes rigoureuses.

Retenue/Défi

Coûts élevés et complexité opérationnelle

• Le coût initial élevé des instruments de spectrométrie de masse, incluant le prix d'achat, l'installation et la maintenance, demeure un obstacle majeur à leur adoption, notamment pour les petits laboratoires et les institutions des régions en développement.
  • Par exemple, le système Orbitrap Fusion Lumos Tribrid coûte plusieurs centaines de milliers de dollars et nécessite une formation spécialisée, un étalonnage et du personnel technique dédié pour un fonctionnement correct, ce qui limite son accessibilité dans les environnements aux ressources limitées.
• Operational complexity and the need for trained staff to handle sample preparation, method development, and data interpretation further restrict widespread adoption
• Ongoing expenses, including consumables, software upgrades, and regular maintenance, contribute to the total cost of ownership, which may deter budget-conscious institutions from investing in advanced systems
• Variations in infrastructure and laboratory capabilities across regions make it challenging to implement mass spectrometry devices uniformly, highlighting the need for simplified, cost-effective, and user-friendly systems to broaden market reach

Asia-Pacific Mass Spectrometry Devices Market Scope

The market is segmented on the basis of technology, application and end user.

• By Technology

On the basis of technology, the Mass Spectrometry Devices market is segmented into Hybrid Mass Spectrometry, Single Mass Spectrometry, and Others. The Hybrid Mass Spectrometry segment dominated the largest market revenue share of 44.5% in 2025, driven by its versatility in combining multiple mass analyzers to deliver high-resolution, accurate mass measurements across complex sample types. This technology is widely preferred in clinical research, metabolomics, and pharmaceutical analysis due to its enhanced sensitivity and precision. Its ability to handle a wide dynamic range and compatibility with advanced separation techniques like LC and GC enhances its adoption. Hybrid systems also facilitate multiplexed analysis, improving laboratory efficiency. Laboratories and research institutes prioritize hybrid systems for high-throughput workflows and comprehensive profiling. The strong presence of leading manufacturers offering innovative hybrid systems further fuels growth. In addition, regulatory acceptance and proven performance in diagnostic and drug discovery applications increase demand. Continuous upgrades and integration with informatics solutions enhance user convenience. The segment’s dominance is supported by rising R&D spending, expanding biotechnology research, and growing investment in proteomics and metabolomics. High reliability, reproducibility, and robust service support also reinforce adoption in key markets.

The Single Mass Spectrometry segment is expected to witness the fastest CAGR of 11.2% from 2026 to 2033, fueled by its cost-effectiveness, simpler operation, and adaptability for targeted applications such as environmental testing, clinical diagnostics, and quality control in pharmaceutical industries. Single MS systems are increasingly favored in emerging markets due to affordability and ease of maintenance. These systems are ideal for labs requiring rapid results with limited resources, supporting routine analysis and smaller-scale research studies. Integration with basic LC and GC workflows allows single MS devices to provide accurate detection at a lower cost, expanding adoption. Growing awareness of mass spectrometry applications in developing countries supports demand growth. Lightweight, portable, and energy-efficient designs further increase appeal. Training and support from manufacturers enable smooth deployment in clinical and academic labs. Rising adoption in small-scale pharmaceutical companies, diagnostics centers, and universities also contributes to market expansion. In addition, government and institutional initiatives promoting analytical research drive uptake. The segment benefits from ongoing innovation in compact instrumentation, reducing operational barriers for end-users.

• By Application

On the basis of application, the Mass Spectrometry Devices market is segmented into Biotechnology, Clinical Research, Diagnostics and Environmental Testing, Drug Discovery, Metabolomics, Pharmaceutical, Proteomics, and Others. The Clinical Research segment dominated the largest market revenue share of 42.8% in 2025, fueled by increasing demand for precision medicine, biomarker discovery, and high-throughput screening. Clinical research laboratories rely on mass spectrometry for quantification of proteins, metabolites, and drug compounds with high accuracy. The integration of MS with separation techniques enables detailed pharmacokinetic and pharmacodynamic studies. Hospitals and research institutions prioritize MS systems for translational research and patient-centered studies. Strong funding for clinical trials in oncology, neurology, and infectious diseases supports growth. The segment benefits from regulatory acceptance for validated analytical methods. Rising collaborations between pharma companies and clinical research organizations further enhance adoption. Increased awareness of personalized medicine, early disease detection, and omics technologies drives the market. High reproducibility, sensitivity, and automation capabilities make MS systems integral to clinical workflows. Ongoing innovation in high-resolution instruments strengthens segment dominance. Expansion of clinical research centers in North America, Europe, and Asia-Pacific further supports market share.

The Drug Discovery segment is expected to witness the fastest CAGR of 10.8% from 2026 to 2033, propelled by the growing need for novel therapeutics, early-stage drug profiling, and high-throughput screening of chemical libraries. Pharmaceutical and biopharmaceutical companies increasingly utilize mass spectrometry to identify lead compounds, study metabolic pathways, and perform structure elucidation. Advanced mass analyzers enable accurate characterization of complex molecules, accelerating drug development timelines. The rise of personalized medicine and biologics fuels demand for MS applications in drug discovery. Cost-effective workflow integration and rapid data acquisition make single and hybrid MS systems suitable for screening laboratories. Investments in research automation and informatics tools further enhance efficiency. Emerging markets with growing pharmaceutical manufacturing capacity are adopting MS systems to streamline discovery pipelines. Regulatory requirements for robust analytical data reinforce market growth. The segment benefits from increasing partnerships between research institutes and pharma companies, strengthening the innovation ecosystem.

• By End-User

On the basis of end-user, the Mass Spectrometry Devices market is segmented into Institutes and Research Centers, Medical, Pharmaceutical and Biopharmaceutical Companies, Suppliers and Distributors of Mass Spectrometry Systems, and Others. The Pharmaceutical and Biopharmaceutical Companies segment dominated the largest market revenue share of 46% in 2025, driven by the increasing adoption of mass spectrometry for drug discovery, formulation, and quality control. These companies leverage MS technology for accurate characterization of drug compounds, protein therapeutics, and small molecules. The growth is further supported by expanding R&D expenditure, stringent regulatory compliance requirements, and the need for faster product development cycles. Pharmaceutical companies prefer hybrid MS systems for high-throughput screening and complex analysis. MS integration with bioinformatics enhances data analysis and accelerates pipeline decisions. Large-scale production, contract research services, and personalized medicine initiatives also boost adoption. Leading pharma players continue to invest in mass spectrometry infrastructure, strengthening market share. Continuous innovation and collaborations with MS vendors enhance capabilities for drug characterization and regulatory reporting.

The Institutes and Research Centers segment is expected to witness the fastest CAGR of 11.5% from 2026 to 2033, fueled by the growing demand for advanced analytical tools in academic research, biotechnology studies, and environmental analysis. These centers prioritize MS systems for teaching, experimentation, and translational research. The increasing establishment of research-focused universities, government-funded labs, and private research institutes expands the potential user base. Rising awareness of omics technologies, metabolomics, and proteomics research drives adoption. Lightweight and modular MS systems enable flexible deployment in multiple lab settings. Collaboration with pharmaceutical and clinical research organizations enhances access to advanced MS technology. Government initiatives promoting science and technology, along with grants for analytical infrastructure, encourage system acquisitions. The segment benefits from the increasing availability of cost-effective MS instruments, training programs, and local technical support.

Asia-Pacific Mass Spectrometry Devices Market Regional Analysis

• The Asia-Pacific mass spectrometry devices market is projected to witness the fastest growth globally during the forecast period of 2026 to 2033, driven by expanding pharmaceutical manufacturing, increasing investments in life sciences research, and rapid modernization of laboratory infrastructure across emerging economies
• Governments across the region are actively strengthening healthcare and research ecosystems through funding initiatives, regulatory reforms, and the establishment of advanced analytical laboratories. Rising demand for high-precision analytical technologies in drug discovery, clinical diagnostics, food safety testing, and environmental analysis is significantly contributing to regional market expansion
• Furthermore, the presence of a strong manufacturing base, improving technical expertise, and growing collaborations between academic institutions and biotechnology firms are accelerating the adoption of advanced mass spectrometry platforms across Asia-Pacific

China Mass Spectrometry Devices Market Insight

China mass spectrometry devices market dominated the Asia-Pacific mass spectrometry devices market with the largest revenue share of 38.4% in 2025, driven by the rapid expansion of its pharmaceutical and biotechnology industries, increasing investments in laboratory infrastructure, and widespread adoption of advanced analytical technologies in research and clinical laboratories. The country has emerged as a global hub for drug development and contract research activities, significantly boosting demand for high-resolution mass spectrometry systems. Strong government support for scientific innovation, expansion of domestic biotechnology companies, and the presence of local manufacturers offering cost-competitive solutions are further propelling market growth. Moreover, increasing regulatory focus on drug safety, food quality testing, and environmental monitoring is accelerating the deployment of advanced analytical platforms across public and private laboratories.

India Mass Spectrometry Devices Market Insight

India mass spectrometry devices market is expected to be the fastest-growing market in the Asia-Pacific mass spectrometry devices sector, expanding at a CAGR of 11.2% from 2026 to 2033. Growth is supported by rising research and development activities, increasing pharmaceutical production, and government initiatives aimed at strengthening analytical and testing capabilities across the country. The expansion of contract research organizations (CROs), growing clinical trial activity, and rising demand for advanced diagnostic solutions are contributing to the increased adoption of mass spectrometry systems. Furthermore, investments in food safety laboratories, environmental monitoring agencies, and academic research institutions are creating additional growth opportunities. As India continues to enhance its healthcare infrastructure and scientific research capacity, the demand for cost-effective, high-performance mass spectrometry devices is expected to increase significantly during the forecast period.

Asia-Pacific Mass Spectrometry Devices Market Share

The Mass Spectrometry Devices industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Waters Corporation (U.S.)
• Bruker Corporation (U.S.)
• Shimadzu Corporation (Japan)
• Danaher Corporation (U.S.)
• PerkinElmer, Inc. (U.S.)
• JEOL Ltd. (Japan)
• LECO Corporation (U.S.)
• Rigaku Corporation (Japan)
• Bio-Rad Laboratories, Inc. (U.S.)
• SCIEX (U.S.)
• Hitachi High-Tech Corporation (Japan)
• Analytik Jena GmbH (Germany)
• Kore Technology Ltd. (U.K.)
• Hiden Analytical Ltd. (U.K.)
• Extrel CMS, LLC (U.S.)
• MKS Instruments, Inc. (U.S.)
• Advion Interchim Scientific (U.S.)
• Tosoh Corporation (Japan)

Latest Developments in Asia-Pacific Mass Spectrometry Devices Market

• In June 2023, Thermo Fisher Scientific launched the Thermo Scientific™ Orbitrap™ Astral mass spectrometer, a high‑performance system designed for precise protein identification and advanced proteomics research — marking a major innovation in mass spectrometry for clinical biomarkers, disease research and therapeutic development
• In June 2023, Agilent Technologies introduced new Inspirational LC/TQ and LC/Q‑TOF mass spectrometry solutions, including the Agilent 6495 Triple Quadrupole LC/MS and the Agilent Revident Quadrupole Time‑of‑Flight LC/MS, offering enhanced sensitivity and operational efficiency for high‑performance mass spectrometry applications
• In February 2024, SCIEX launched the Echo MS+ system, which integrates proprietary Acoustic Ejection Mass Spectrometry (AEMS) and Open Port Interface (OPI) sampling with high‑throughput capabilities to deliver precise qualitative and quantitative mass spectrometry results
• In January 2024, Shimadzu Scientific Instruments introduced the GC‑MS‑QP2050 gas chromatograph mass spectrometer and the ICPMS‑2040/2050 series of inductively coupled plasma mass spectrometers, bringing advanced automation, improved resolution, and enhanced sensitivity to routine analytical testing workflows
• In June 2024, Thermo Fisher Scientific unveiled its Stellar mass spectrometer platform at the American Society for Mass Spectrometry (ASMS) conference, emphasizing fast throughput, high sensitivity and streamlined workflows for translational omics research
• In June 2024, Agilent Technologies showcased next‑generation instrumentation at ASMS 2024, including the ultra‑high‑performance 7010D Triple Quadrupole GC/MS System and the ExD Cell for the 6545XT AdvanceBio LC/Q‑TOF system, designed to broaden analytical capabilities for food safety and biopharmaceutical research
• In December 2024, Roche Diagnostics received CE mark approval and launched its cobas Mass Spec solution, including the cobas i 601 Analyzer and Ionify reagent pack, enabling fully automated, integrated and standardized clinical mass spectrometry testing across a wide menu of analytes for routine laboratory diagnostics
• In May 2025, Agilent Technologies unveiled the Agilent InfinityLab Pro iQ Series, a next‑generation LC‑mass detection platform aimed at enhancing sensitivity, intelligent data processing and sustainability in high‑resolution mass detection for pharmaceutical, environmental, food safety and research applications
• In June 2025, Thermo Fisher Scientific introduced the Orbitrap Astral Zoom MS and Orbitrap Excedion Pro MS at ASMS 2025, advancing mass spectrometry performance with increased analytical speed, broader dynamic range and enhanced capabilities for complex biological and biopharmaceutical research
• En juillet 2025, 1st Detect, filiale d'Astrotech Corporation, a annoncé la première vente de son système TRACER 1000 NTD au Vietnam – une plateforme de détection de traces de stupéfiants basée sur la spectrométrie de masse, marquant un déploiement commercial clé de la technologie de sécurité et de contrôle basée sur la spectrométrie de masse en Asie du Sud-Est.

SKU-1510